TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27176449

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE) group (n = 80)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (n = 37)
Number of subjects: 117
Study: 25358227

Group type: EXPERIMENTAL
Intervention: Volar subcutaneous digital block
Number of subjects: 126

Group type: COMPARATOR
Intervention: Dorsal two injections block
Number of subjects: 126
Study: 22515905

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl containing 9% (wt/vol) etidronic acid (HEBP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 60
Study: 20544310

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study: 18600509

Group type: EXPERIMENTAL
Intervention: urate-lowering agents
Number of subjects: 1832

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1832
Study: 15980629

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 or 7-10 days
Number of subjects: 327
Study: 12054164

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (mean dose, 0.18 IU/kg per week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 100
Study: 10472588

Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7767551

Group type: EXPERIMENTAL
Intervention: Inhaled Atrial Natriuretic Peptide (ANP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thiorphan (NEP inhibitor) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled Atrial Natriuretic Peptide (ANP) with Thiorphan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2181102

Group type: EXPERIMENTAL
Intervention: Intravenous and oral zidovudine therapy (80, 120, or 160 mg/m2/dose, with oral dose being 1.5 times the intravenous dosage)
Number of subjects: 35
Study: 7373510

Group type: EXPERIMENTAL
Intervention: Similar partners (homosexual or heterosexual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterosexual partners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homosexual partners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liberal attitudes
Number of subjects: 0
Study: 31800986

Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Number of subjects: 20019

Group type: COMPARATOR
Intervention: Capsular group A meningococcal conjugate vaccine (MenA)
Number of subjects: 20019
Study: 28376846

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 0
Study: 26359188

Group type: EXPERIMENTAL
Intervention: Systemic therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intravitreal fluocinolone acetonide implant therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Resolution of macular edema
Number of subjects: 108

Group type: COMPARATOR
Intervention: Improvement without resolution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Little to no change
Number of subjects: 108

Group type: COMPARATOR
Intervention: Worsening
Number of subjects: 108
Study: 23426452

Group type: EXPERIMENTAL
Intervention: New Structured Pathway (NSP)
Number of subjects: 231
Study: 21270141

Group type: EXPERIMENTAL
Intervention: Two-session brief motivational intervention delivered to students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Handbook-based parent intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19476631

Group type: EXPERIMENTAL
Intervention: High antioxidant diet (HAD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 83
Study: 19042478

Group type: EXPERIMENTAL
Intervention: Alert Program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 15677729

Group type: EXPERIMENTAL
Intervention: C34T AMPD1 genotype carriers
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: C34T AMPD1 genotype noncarriers
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (nonathletes)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Athlete group
Number of subjects: 104
Study: 11896510

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Withdrawal of calcium antagonists
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Continued treatment with calcium antagonists
Number of subjects: 156
Study: 10573634

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation (Neoral)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional formulation (Sandimmune)
Number of subjects: 23
Study: 7613098

Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 2
Study: 2620952

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg d-tubocurarine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg succinylcholine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg pancuronium bromide
Number of subjects: 45
Study: 330851

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 gram intramuscularly preoperatively)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephaloridine (given preoperatively and postoperatively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 0
Study: 30725091

Group type: EXPERIMENTAL
Intervention: Trimetazidine, 20 mg, 3 times daily (n=27)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n=24)
Number of subjects: 51
Study: 28346567

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean Diet (LGIMD)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 98
Study: 26267984

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib administered 1 hour before surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo administered 1 hour before surgery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 120
Study: 22717960

Group type: EXPERIMENTAL
Intervention: Polydextrose-containing smoothie (12 g, 3%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Polydextrose-free control smoothie
Number of subjects: 26
Study: 20920384

Group type: EXPERIMENTAL
Intervention: Educational intervention for educators in four day-care centres
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (no intervention) in four other day-care centres
Number of subjects: 252
Study: 19243946

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 13
Study: 16739544

Group type: EXPERIMENTAL
Intervention: AL irradiation alone at 13.5 joules per square centimeters (0.270 watts, 5‐millimeter beam, 10 seconds)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RS treatment alone for two minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AL irradiation before RS treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 10
Study: 15562040

Group type: EXPERIMENTAL
Intervention: Fenoldopam, 0.1 microg . kg(‐1) . min(‐1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dopamine, 2 microg . kg(‐1) . min(‐1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 43
Study: 12092185

Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor) administered to 86% of cases at therapeutic doses for 6 months to one year
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study: 9444579

Group type: EXPERIMENTAL
Intervention: Conservative treatment based on bedrest for a minimum of two weeks
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Conservative treatment (no surgery)
Number of subjects: 322
Study: 7942489

Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Treadmill vs Bicycle exercise
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) response to exercise
Number of subjects: 140
Study: 2896636

Group type: EXPERIMENTAL
Intervention: levocabastine nasal spray
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 31159674

Group type: EXPERIMENTAL
Intervention: Youth Aware of Mental Health (YAM) intervention delivered in 78 classes
Number of subjects: 1878
Study: 30667510

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback-assisted exercise programme
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham electromyographic biofeedback
Number of subjects: 34
Study: 28628402

Group type: EXPERIMENTAL
Intervention: Mineral waters with different concentrations of minerals
Number of subjects: 21

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 21

Group type: COMPARATOR
Intervention: Calcium supplement
Number of subjects: 21
Study: 26639849

Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) 600 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) 300 mg repeated ingestion for 8 days
Number of subjects: 0
Study: 24273887

Group type: EXPERIMENTAL
Intervention: Calcium gluconate plus calcitriol (arm C)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (arm A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Calcium gluconate (arm B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo or calcium gluconate (arms A and B combined)
Number of subjects: 75
Study: 20414685

Group type: EXPERIMENTAL
Intervention: 12 weeks of group psychotherapy
Number of subjects: 317
Study: 18971536

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for 24 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily for 24 weeks
Number of subjects: 32
Study: 16819695

Group type: EXPERIMENTAL
Intervention: Elastic stockinette (E)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cast padding (C)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No protective material (N)
Number of subjects: 92
Study: 12710221

Group type: EXPERIMENTAL
Intervention: Inhibitory tasks (negative priming, stopping, continuous performance tasks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Working memory capacity test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitory deficit hypothesis
Number of subjects: 0
Study: 10739171

Group type: COMPARATOR
Intervention: Dopamine D2 and D3 receptor gene polymorphisms
Number of subjects: 0

Group type: COMPARATOR
Intervention: C allele of the TaqIA polymorphism
Number of subjects: 0
Study: 9358666

Group type: EXPERIMENTAL
Intervention: 3-drug antitubercular treatment (group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 25
Study: 1480310

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (50 mg tablet, 3 times daily for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oxerutin (1,500 mg tablet, 3 times daily for 2 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study: 2951198

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 to 20 mg at night)
Number of subjects: 14
Study: 30636269

Group type: EXPERIMENTAL
Intervention: Real World Evidence (RWE)
Number of subjects: 0
Study: 26991772

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg daily for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 42
Study: 25155966

Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: rhEPO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both rhG‐CSF and rhEPO
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 90
Study: 22025228

Group type: EXPERIMENTAL
Intervention: Histopathological examination by two pathologists
Number of subjects: 678
Study: 19833797

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in patients with preserved speech
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) in nonverbal patients or those speaking only single words
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clinical features correlation
Number of subjects: 32
Study: 18490027

Group type: EXPERIMENTAL
Intervention: Imitation of the model's path
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spontaneous play with goal objects
Number of subjects: 34
Study: 15839735

Group type: EXPERIMENTAL
Intervention: Music therapy (song)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Karaoke accompaniment
Number of subjects: 10

Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 10
Study: 14664673

Group type: EXPERIMENTAL
Intervention: Active VE exploration with a map
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active VE exploration without a map
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive VE training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VE + map training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with a map alone
Number of subjects: 0
Study: 10841872

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Number of subjects: 60

Group type: COMPARATOR
Intervention: Large-volume paracentesis
Number of subjects: 60
Study: 8815088

Group type: EXPERIMENTAL
Intervention: PCR diagnostic sensitivity for B. pertussis among Chelex-treated aspirates
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: PCR diagnostic sensitivity for B. pertussis among non-Chelex-treated aspirates
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Final sensitivity after Chelex treatment of PCR-negative samples
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: PCR positive for B. pertussis with culture-negative samples
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: PCR diagnostic sensitivity for B. parapertussis
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Additional culture-negative B. parapertussis PCR findings
Number of subjects: 2421
Study: 1511712

Group type: EXPERIMENTAL
Intervention: PAC regimen (Cisplatin + Cyclophosphamide + Doxorubicin)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: PAC regimen
Number of subjects: 125

Group type: COMPARATOR
Intervention: PC regimen (Cisplatin + Cyclophosphamide)
Number of subjects: 125
Study: 6673080

Group type: EXPERIMENTAL
Intervention: Colorectal examination every 6 months (Group A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Colorectal examination every 24 months (Group B)
Number of subjects: 156
Study: 31383985

Group type: EXPERIMENTAL
Intervention: Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy alone
Number of subjects: 218
Study: 27155856

Group type: EXPERIMENTAL
Intervention: Irradiated hamstring tendon allograft (Ir‐Allo)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non‐irradiated hamstring tendon allograft (Non‐ir‐Allo)
Number of subjects: 112
Study: 26421292

Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.45 mg ramosetron
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.6 mg ramosetron
Number of subjects: 50
Study: 23340914

Group type: EXPERIMENTAL
Intervention: Educational sessions with pharmaceutical representatives and counterdetailing sessions by a clinical pharmacist
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Counterdetailing sessions
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Counterdetailing presentations
Number of subjects: 27
Study: 22008919

Group type: EXPERIMENTAL
Intervention: Combined sevoflurane general and epidural anesthesia (group S1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Standard sevoflurane general anesthesia (group S2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined propofol general and epidural anesthesia (group P1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard propofol general anesthesia (group P2)
Number of subjects: 80
Study: 19158371

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1253
Study: 17414930

Group type: EXPERIMENTAL
Intervention: Micronutrients with 18 mg of iron
Number of subjects: 458

Group type: COMPARATOR
Intervention: Micronutrients without iron (control group)
Number of subjects: 458
Study: 15682799

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 0.2% ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.2% ropivacaine with fentanyl (CEA)
Number of subjects: 40
Study: 16316365

Group type: EXPERIMENTAL
Intervention: Oral feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.86% glucose-based dialysate PD exchange
Number of subjects: 10
Study: 10510139

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 5 mg twice daily (preschool Caucasians)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 10 mg once daily (preschool Caucasians)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 10 mg once daily (Caucasian school children)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 20 mg once daily (Caucasian school children)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 2.5 mg once daily (Oriental preschool children)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 5 mg once daily (Oriental preschool children)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 10 mg once daily (Oriental school children)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bambuterol hydrochloride 20 mg once daily (Oriental school children)
Number of subjects: 48
Study: 7577283

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg kg‐1 i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study: 1685458

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg per capsule, 2 capsules once daily for 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (2 capsules once daily for 3 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7139566

Group type: EXPERIMENTAL
Intervention: Adriamycin (70 mg/m2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vincristine (1.4 mg/m2) and Adriamycin (50 mg/m2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cyclophosphamide (750 mg/m2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vincristine-cyclophosphamide-Adriamycin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adriamycin alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adriamycin combination
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vincristine-actinomycin-D-cyclophosphamide
Number of subjects: 200
Study: 31421858

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other treatments (including lithium)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 10
Study: 30660594

Group type: EXPERIMENTAL
Intervention: Financial incentives for viral suppression at weeks 6, 12, and 24, with amounts increasing from US$4 to $12.5.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no financial incentives).
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Financial incentives for viral suppression.
Number of subjects: 400
Study: 28222546

Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (CIMTm) - collective modality
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (CIMTm) - individual modality
Number of subjects: 36
Study: 27162126

Group type: EXPERIMENTAL
Intervention: MGDRx Eyebag(®)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EyeDoctor(®)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bruder(®)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tranquileyes XR™
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thera°Pearl(®)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Facecloth warmed with hot tap water
Number of subjects: 12
Study: 24457061

Group type: EXPERIMENTAL
Intervention: Postplacental insertion of LNG-IUD
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUD
Number of subjects: 42
Study: 22410289

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 × 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valsartan 2 × 160 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pitavastatin + Valsartan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Valsartan monotherapy
Number of subjects: 24
Study: 19508973

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - three 5 min cycles of right forearm ischaemia with 5 min reperfusion, after anaesthesia.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control - deflated cuff placed on the upper arm for 30 min after anaesthesia.
Number of subjects: 45
Study: 17239682

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mobilized peripheral blood stem cells (PBSCs) with G-CSF
Number of subjects: 3

Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mobilized PBSCs with G-CSF
Number of subjects: 3

Group type: COMPARATOR
Intervention: G-CSF administration
Number of subjects: 3
Study: 15599747

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenous at induction of anesthesia)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Cefotaxime (1 g intravenous at induction of anesthesia)
Number of subjects: 1013
Study: 11954897

Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS (0.8, 1.2, and 1.6 mg)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo TDS
Number of subjects: 445